Bridgebio Pharma Inc (BBIO)

$73.68 -1.08 (-1.44%)
Market Cap 13.77B
Revenue (ttm) 221.90M
Net Income (ttm) -535.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -241.44%
Debt to Equity Ratio -0.96
Volume 1,504,734
Avg Vol 2,337,098
Day's Range N/A - N/A
Shares Out 192.71M
Stochastic %K 98%
Beta 1.26
Analysts Strong Sell
Price Target $84.39

Company Profile

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 doub...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 391 9740
Address:
3160 Porter Drive, Suite 250, Palo Alto, United States
Quantumup
Quantumup Dec. 5 at 1:17 PM
Morgan Stanley🏁 $BBOT Overweight/$20 $BBIO $RVMD Here's what Morgan Stanley had to say: https://x.com/Quantumup1/status/1996931177412804795?s=20
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Dec. 5 at 2:33 AM
$BBIO this is going to have a 12-15% day rip soon. Still way underpriced. 💥💥💥🚀🚀🚀
1 · Reply
LMXPERTEN
LMXPERTEN Dec. 4 at 7:14 PM
$BBIO 🚂
0 · Reply
knobs101
knobs101 Dec. 4 at 3:58 PM
$BBIO Higher highs and higher lows. Mi gusta.
0 · Reply
WAJeff
WAJeff Dec. 4 at 3:50 PM
$BBIO 75.04 ath
0 · Reply
StockBraker
StockBraker Dec. 4 at 3:44 PM
$BBIO New 52 week high. Personally looking for $85+ to start trimming holdings.
0 · Reply
Quantumup
Quantumup Dec. 4 at 1:26 PM
Goldman Sachs🏁 $TYRA at an Early-Stage Biotech rating. $BBIO $JNJ $INCY $OTSKY Here's what Goldman Sachs had to say in its initiation report: https://x.com/Quantumup1/status/1996570205779099845?s=20
0 · Reply
HedgeAlerts
HedgeAlerts Dec. 4 at 6:59 AM
Hedge Alert Live - Protect Your Portfolio Contract: $BBIO $72.50 Put · DEC 19, 2025 Exp Entry Price: $3.00 - $3.90 Exit Price Target: $6.48 Profit Margin: +116% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
justiceforb_85
justiceforb_85 Dec. 4 at 2:44 AM
$BBIO continues to impress. Bright future with pending FDA approvals for rare diseases without approved therapies.
0 · Reply
Jblack500
Jblack500 Dec. 3 at 9:00 PM
$BBIO on a breakout...the measured move eventually grinds to about 135-138
0 · Reply
Latest News on BBIO
BridgeBio to Participate in December Investor Conferences

Nov 25, 2025, 7:30 AM EST - 10 days ago

BridgeBio to Participate in December Investor Conferences

BridgeBio Pharma: Set For New Commercial Launches After Trial Successes

Nov 23, 2025, 7:04 AM EST - 12 days ago

BridgeBio Pharma: Set For New Commercial Launches After Trial Successes

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Nov 19, 2025, 4:01 PM EST - 16 days ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma, Inc. (BBIO) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 10, 2025, 8:21 PM EST - 24 days ago

BridgeBio Pharma, Inc. (BBIO) Presents at UBS Global Healthcare Conference 2025 Transcript

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

Nov 8, 2025, 10:41 AM EST - 27 days ago

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

National Advertising Division Will Refer BridgeBio Pharma to Government Agencies for Failure to Participate in Inquiry

Nov 7, 2025, 1:00 PM EST - 4 weeks ago

National Advertising Division Will Refer BridgeBio Pharma to Government Agencies for Failure to Participate in Inquiry

BridgeBio to Participate in November Investor Conferences

Nov 4, 2025, 7:30 AM EST - 4 weeks ago

BridgeBio to Participate in November Investor Conferences

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

Nov 3, 2025, 9:58 AM EST - 4 weeks ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MBX MDGL

BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025

Nov 3, 2025, 7:30 AM EST - 4 weeks ago

BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025

BridgeBio Pharma: Bullish On Attruby's Momentum And 2026 Catalysts

Oct 31, 2025, 2:33 PM EDT - 5 weeks ago

BridgeBio Pharma: Bullish On Attruby's Momentum And 2026 Catalysts

BridgeBio Pharma, Inc. (BBIO) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 10:56 PM EDT - 5 weeks ago

BridgeBio Pharma, Inc. (BBIO) Q3 2025 Earnings Call Transcript

BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates

Oct 29, 2025, 4:01 PM EDT - 5 weeks ago

BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates

BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase III Results for Encaleret in ADH1 CALIBRATE Study Transcript

Oct 29, 2025, 12:06 PM EDT - 5 weeks ago

BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase III Results for Encaleret in ADH1 CALIBRATE Study Transcript

BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1

Oct 29, 2025, 7:00 AM EDT - 5 weeks ago

BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1

BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th

Oct 28, 2025, 4:01 PM EDT - 5 weeks ago

BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th

BridgeBio Pharma, Inc. (BBIO) Discusses Positive FORTIFY Phase III Interim Results in Limb-Girdle Muscular Dystrophy Type 2I/R9 Transcript

Oct 27, 2025, 11:17 AM EDT - 5 weeks ago

BridgeBio Pharma, Inc. (BBIO) Discusses Positive FORTIFY Phase III Interim Results in Limb-Girdle Muscular Dystrophy Type 2I/R9 Transcript

BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study

Oct 27, 2025, 7:00 AM EDT - 5 weeks ago

BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study

BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week

Oct 24, 2025, 4:01 PM EDT - 6 weeks ago

BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week

Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM

Sep 28, 2025, 11:15 AM EDT - 2 months ago

Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM

BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025

Sep 22, 2025, 7:30 AM EDT - 2 months ago

BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025

BridgeBio Pharma, Inc. (BBIO) Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar Call (Transcript)

Sep 10, 2025, 12:33 PM EDT - 3 months ago

BridgeBio Pharma, Inc. (BBIO) Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar Call (Transcript)

BridgeBio Pharma, Inc. (BBIO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 8, 2025, 6:04 PM EDT - 3 months ago

BridgeBio Pharma, Inc. (BBIO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism

Sep 6, 2025, 2:30 PM EDT - 3 months ago

Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism

BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET

Sep 3, 2025, 7:30 AM EDT - 3 months ago

BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET

BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism

Sep 2, 2025, 7:30 AM EDT - 3 months ago

BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism

Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension

Aug 30, 2025, 7:15 AM EDT - 3 months ago

Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension

BridgeBio to Participate in September Investor Conferences

Aug 27, 2025, 7:30 AM EDT - 3 months ago

BridgeBio to Participate in September Investor Conferences

BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025

Aug 25, 2025, 7:30 AM EDT - 3 months ago

BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025

‘BUY THAT THING': Historically undervalued stock now has value, says wealth expert

Aug 19, 2025, 5:30 PM EDT - 3 months ago

‘BUY THAT THING': Historically undervalued stock now has value, says wealth expert

BridgeBio Pharma, Inc. (BBIO) Q2 2025 Earnings Call Transcript

Aug 9, 2025, 4:30 AM EDT - 4 months ago

BridgeBio Pharma, Inc. (BBIO) Q2 2025 Earnings Call Transcript

BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates

Aug 5, 2025, 4:01 PM EDT - 4 months ago

BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates

Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains.

Jul 30, 2025, 12:37 PM EDT - 4 months ago

Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains.

AMGN INSM

Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1

Jul 23, 2025, 7:30 AM EDT - 4 months ago

Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1

BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET

Jul 22, 2025, 7:30 AM EDT - 4 months ago

BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET

It is time for a move higher in biotech, says Mizuho's Jared Holz

Jul 7, 2025, 6:29 PM EDT - 5 months ago

It is time for a move higher in biotech, says Mizuho's Jared Holz

BMRN GILD INSM XBI

BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty

Jun 30, 2025, 7:30 AM EDT - 5 months ago

BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty

BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET

Jun 26, 2025, 7:30 AM EDT - 5 months ago

BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET

BridgeBio: New Data Bolsters The Bull Case

Jun 4, 2025, 3:34 AM EDT - 6 months ago

BridgeBio: New Data Bolsters The Bull Case

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 2, 2025, 7:30 AM EDT - 6 months ago

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM

May 20, 2025, 7:30 AM EDT - 7 months ago

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM

Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study

May 19, 2025, 12:33 PM EDT - 7 months ago

Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study

May 13, 2025, 7:30 AM EDT - 7 months ago

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study

BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC

May 12, 2025, 7:30 AM EDT - 7 months ago

BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC

BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025

May 7, 2025, 7:30 AM EDT - 7 months ago

BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025

BridgeBio Pharma, Inc. (BBIO) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 9:43 PM EDT - 7 months ago

BridgeBio Pharma, Inc. (BBIO) Q1 2025 Earnings Call Transcript

BridgeBio Reports First Quarter 2025 Financial Results and Business Updates

Apr 29, 2025, 4:01 PM EDT - 7 months ago

BridgeBio Reports First Quarter 2025 Financial Results and Business Updates

BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

Apr 28, 2025, 5:00 AM EDT - 7 months ago

BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

BridgeBio: Early Signs Point To Blockbuster Revenues

Apr 22, 2025, 11:14 AM EDT - 8 months ago

BridgeBio: Early Signs Point To Blockbuster Revenues

BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

Apr 22, 2025, 7:30 AM EDT - 8 months ago

BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

Quantumup
Quantumup Dec. 5 at 1:17 PM
Morgan Stanley🏁 $BBOT Overweight/$20 $BBIO $RVMD Here's what Morgan Stanley had to say: https://x.com/Quantumup1/status/1996931177412804795?s=20
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Dec. 5 at 2:33 AM
$BBIO this is going to have a 12-15% day rip soon. Still way underpriced. 💥💥💥🚀🚀🚀
1 · Reply
LMXPERTEN
LMXPERTEN Dec. 4 at 7:14 PM
$BBIO 🚂
0 · Reply
knobs101
knobs101 Dec. 4 at 3:58 PM
$BBIO Higher highs and higher lows. Mi gusta.
0 · Reply
WAJeff
WAJeff Dec. 4 at 3:50 PM
$BBIO 75.04 ath
0 · Reply
StockBraker
StockBraker Dec. 4 at 3:44 PM
$BBIO New 52 week high. Personally looking for $85+ to start trimming holdings.
0 · Reply
Quantumup
Quantumup Dec. 4 at 1:26 PM
Goldman Sachs🏁 $TYRA at an Early-Stage Biotech rating. $BBIO $JNJ $INCY $OTSKY Here's what Goldman Sachs had to say in its initiation report: https://x.com/Quantumup1/status/1996570205779099845?s=20
0 · Reply
HedgeAlerts
HedgeAlerts Dec. 4 at 6:59 AM
Hedge Alert Live - Protect Your Portfolio Contract: $BBIO $72.50 Put · DEC 19, 2025 Exp Entry Price: $3.00 - $3.90 Exit Price Target: $6.48 Profit Margin: +116% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
justiceforb_85
justiceforb_85 Dec. 4 at 2:44 AM
$BBIO continues to impress. Bright future with pending FDA approvals for rare diseases without approved therapies.
0 · Reply
Jblack500
Jblack500 Dec. 3 at 9:00 PM
$BBIO on a breakout...the measured move eventually grinds to about 135-138
0 · Reply
Jblack500
Jblack500 Dec. 3 at 8:53 PM
$BBIO $GILD $ABBV $ABVX $PFE healthcare sector heating up for 2026. Will see a lot of m&a in 2026...oncology will be a target which makes EXEL a possibility....ABVX has a blockbuster on their hands and I could absolutely see them acquired for 12 to 14 billion
0 · Reply
KenCowboys
KenCowboys Dec. 3 at 8:19 PM
$ARWR wow, this and $BBIO have been my best bios ever
1 · Reply
BillionerOfKing
BillionerOfKing Dec. 3 at 6:35 PM
$BBIO Current Stock Price: $72.79 Contracts to trade: $70 BBIO Dec 19 2025 Call Entry: $4.00 Exit: $5.10 ROI: 28% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Dec. 3 at 3:43 PM
$ALT $CAPR $BBAI $BBIO $ALMS 💥💥💥💥BANG💥💥💥💥
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Dec. 3 at 2:51 PM
$ALT $CAPR $BBAI $BBIO $ALMS Capr today ALT soon! Christmas is coming early.
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Dec. 3 at 12:31 PM
$BBIO this has to be one of the most undervalued biotechs. 2 more products likely to come to market in the next 12 months, yet the price action is very muted. https://www.investors.com/news/technology/bridgebio-pharma-stock-2025/
1 · Reply
WAJeff
WAJeff Dec. 2 at 2:52 PM
$BBIO $72.78 52 week high, looks like an ath?
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Dec. 2 at 4:14 AM
Folks I gave you banggers. $ALT : new ceo with leadership experience selling multiple companies. $CAPR binary event could be yuge. $BBAI bears gave you an opportunity to buy pltr at single digits. $BBIO catalysts keep rolling. Santa rally takes this to 80 by eoy. $ALMS data from p3 is rolling in and insiders are buying. Reminds me of tern at $5 . P3 due soon. Krknf unknown name to many, already a game changer in sea drone technology. Currently under 4 dollars. Prme took a big hit from NTLA failure, not connected to ntla at all. Dirt cheap at 3.5 🔥🔥🔥🚀🚀🚀
1 · Reply
BIOTECH_GURU
BIOTECH_GURU Dec. 2 at 12:32 AM
$BBIO HR 1262 passed. Lots of biotechs stand to benifit. Bbio Capr Prme To name a few
0 · Reply
HedgeAlerts
HedgeAlerts Dec. 1 at 9:51 PM
Hedge Alert Live - Protect Your Portfolio Contract: $BBIO $70.00 Put · DEC 19, 2025 Exp Entry Price: $2.00 - $2.70 Exit Price Target: $2.74 Profit Margin: +37% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
knobs101
knobs101 Nov. 26 at 6:19 PM
$BBIO Started to accumulate this company a few years ago at just under 17 when I saw it on the "unusual volume" report. Now I hold their JAN 2027 65 Calls. What a run.
0 · Reply
WAJeff
WAJeff Nov. 26 at 4:15 PM
$BBIO $72 52 week high
0 · Reply